Andrea Riposati Grows Dante Labs

Andrea Riposati co-founded Dante Genomics, a global genomic information company building a new class of transformative health through longevity and wellness solutions. He has over 15 years of experience leading and driving innovation for high-growth start-ups and multinational corporations.

Andrea Riposati currently serves as CEO of Dante Labs, Inc., a Los Angeles-based company building up its genetic laboratory from scratch to become the new standard in the genomic testing industry. He also co-founded 3DNA Solutions LLC, an R&D company developing innovative therapeutics for neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS).

His Achievements

He currently serves as CEO of Dante Labs, a company building up its genetic laboratory from scratch to become the new standard in the genomic testing industry. He also co-founded 3DNA Solutions LLC, an R&D company developing innovative therapeutics for neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), pancreatic cancer, and others.

Riposati received his undergraduate degree in Business Administration from Colegio Americano de Buenos Aires (BA), Argentina. He also holds a Master of Science degree in Biomedical Sciences from UCLA, where he focused on Human Genome Sequencing and Bioinformatics. He completed his Ph.D. focusing on Non-coding RNA in Transcriptional Regulation and Cancer.

Riposte has received awards and grants from the National Institute of Health, National Science Foundation, Human Frontier Science Program (HFSP), Technology Accelerator Fund (TAF), The Leona M. & Harry B. Helmsley Charitable Trust, the California Institute for Regenerative Medicine (CIRM) and others. He has published research papers in high-impact journals such as Science, Nature Genetics, and Genome Research.

Andrea Riposati has compiled his entrepreneurial endeavors into a career at the forefront of biotechnology and science. He co-founded 3DNA Solutions LLC, an R&D company developing innovative therapeutics for neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), pancreatic cancer, and others. His achievements include the development of new technology for the rapid detection of mutations in the human genome, and he has developed new technologies for genome editing with therapeutic potential.